[의학신문·일간보사=김민지 기자] Dongkook Pharmaceutical (CEO Song Jun-ho) announced on the 13th that it had signed a business agreement with Epil Bioscience (CEO Kim Jeong-hoon) to promote joint research on new drug development projects.
” src=”http://cdn.bosa.co.kr/news/photo/202206/2175279_206783_5253.jpg”/>
The signing ceremony was held at the Dongkuk Pharmaceutical headquarters on the 10th. Dongkook Pharmaceutical and Epibioscience are aiming to develop promising new drugs in the field of common interest.
In particular, we expect that we will be able to create synergy in joint research for new drug development by utilizing their expertise in non-clinical efficacy tests using the ‘Cholesterol Metabolism Inhibitor Library’, drug delivery system (DDS), product commercialization, approval, and marketing. have.
The two companies plan to form a joint committee in the future to cooperate in the overall process related to new drug development and commercialization, including discovery and derivation of candidate substances, securing patents and rights, and licensing out (technology export). It aims to derive one or more non-clinical candidates by the end of this year, and to conduct non-clinical research for full-scale clinical trials (IND) in 2023.
Lee Gye-wan, head of Dongkook Pharmaceutical’s research institute, who attended the signing ceremony said, “Epil Bioscience is a promising company that not only has an excellent R&D pipeline, but is also conducting various joint research with leading American universities.” , we plan to create synergies and drive performance by combining our production capacity and DDS (Drug Delivery System) platform technology.”
“I am very excited to work with Dongkook Pharmaceutical, which has excellent new drug development platform technology and capabilities,” said Kim Jeong-hoon, CEO of Epilbioscience.
